The Chronic Pulmonary Hypertension Market to Exhibit Growth at a Massive 28.14% CAGR During the Study Period (2019–2032), Assesses DelveInsight

Nevada (Las Vegas), United States, DelveInsight’s “Chronic Pulmonary Hypertension – Market Insight, Epidemiology and Market Forecast – 2032” report provides current treatment practices, emerging drugs, Chronic Pulmonary Hypertension market share of the individual therapies, current and forecasted Chronic Pulmonary Hypertension market size from 2019 to 2032 segmented by seven major markets. The report also offers current Chronic Pulmonary Hypertension therapy algorithms, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Chronic Pulmonary Hypertension market.

Chronic Pulmonary Hypertension Overview
Pulmonary hypertension refers to a group of conditions characterized by increased pulmonary vascular resistance. Pulmonary hypertension is a progressive condition that requires symptom management and treatment of underlying diseases. Individuals with pulmonary hypertension can generally live for up to 5 years, but the Pulmonary Hypertension life expectancy is improving over time.

High blood pressure in the lungs’ arteries caused by some types of congenital heart disease, connective tissue disease, coronary artery disease, high blood pressure, liver disease (cirrhosis), blood clots to the lungs, and chronic lung diseases such as emphysema are some of the most common underlying causes of Chronic Pulmonary Hypertension.

The symptoms of pulmonary hypertension are similar to those of many other medical disorders in the early stages of the disease (e.g., difficulty breathing, fatigue). This can result in a delayed diagnosis until more serious Chronic Pulmonary Hypertension symptoms appear, such as dizziness, chest pain, ankle swelling, or feeling your heart race or pound (palpitations).

The diagnosis of Chronic Pulmonary Hypertension is sometimes delayed because the symptoms overlap with those of other diseases. Other disorders to be considered in the differential diagnosis of Chronic Pulmonary Hypertension include congestive heart failure, coronary artery disease, pulmonary fibrosis, chronic obstructive pulmonary disease, valvular heart disease, hypothyroidism, and pulmonary embolism.

Chronic Pulmonary Hypertension Epidemiological Insights
The disease epidemiology covered in the report provides historical and forecasted Chronic Pulmonary Hypertension epidemiology segmented as the Total Prevalent cases of Chronic Pulmonary Hypertension, Group-specific Prevalence of Chronic Pulmonary Hypertension, Gender-specific prevalent cases of Chronic Pulmonary Hypertension, and Age-specific prevalent cases of Chronic Pulmonary Hypertension. The report includes the Chronic Pulmonary Hypertension scenario in the 7MM, covering the United States, the EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.

As per DelveInsight, there was more than 42 million Chronic Pulmonary Hypertension prevalent population in the 7MM in 2021. Among EU5 countries, Germany had the highest Chronic Pulmonary Hypertension prevalence in 2021.

Chronic Pulmonary Hypertension Treatment Market
Several medications are available to help alleviate pulmonary hypertension symptoms and slow disease progression. Blood vessel dilators (vasodilators) (Flolan, Veletri, Tyvaso, Remodulin, and Orenitram), guanylate cyclase (GSC) stimulators, endothelin receptor antagonists (bosentan, macitentan, and ambrisentan), and high-dose calcium channel blockers are currently used to treat chronic pulmonary hypertension (amlodipine, diltiazem, nifedipine).

Digoxin (Lanoxin), diuretics, and oxygen therapy are also recommended drugs for the treatment of pulmonary hypertension. If medications do not control the signs and symptoms of pulmonary hypertension, surgical procedures such as atrial septostomy and lung or heart-lung transplant are recommended.

Promising Therapies in the Chronic Pulmonary Hypertension Pipeline
• Supernitro (PDNO)
• CS1
• Zamicastat (BIA 5-1058)
• YUTREPIA (LIQ861 Inhaled Treprostinil)
• INOpulse® A
• Levosimendan
• Treprostinil palmitil
• Rodatristat Ethyl

Discover more about Chronic Pulmonary Hypertension therapies in the pipeline @ Chronic Pulmonary Hypertension Drugs

Leading Companies Working in the Chronic Pulmonary Hypertension Market
• Bayer
• Attgeno AB
• Cereno Scientific AB
• Bial – Portela C S.A
• Liquidia Technologies
• Bellerophon Therapeutics
• AbbVie
• Tenax Therapeutics
• Insmed
• Altavant Sciences

Learn more about the recent developments and breakthroughs in the Chronic Pulmonary Hypertension market @ Chronic Pulmonary Hypertension Clinical Trials

Chronic Pulmonary Hypertension Market Dynamics
Pulmonary hypertension is a constantly evolving field in which clinicians face a slew of diagnostic and treatment challenges. Pulmonary hypertension is a complex disease that rarely manifests as an isolated entity and is more frequently associated with one or more predisposing factors, exposures, or disease states. Clinical disease development and outcomes vary greatly between individuals, and there is no generally successful Chronic Pulmonary Hypertension treatment method, even within a specific form of Pulmonary Hypertension.

According to DelveInsight estimates, the Chronic Pulmonary Hypertension market size was USD 94,693.26 million in 2021.

Furthermore, the recent emergence of promising pipelines and successful drug approvals has given the Chronic Pulmonary Hypertension market a significant boost. This is also a major driver of the Chronic Pulmonary Hypertension market’s growth and development.

Scope of the Chronic Pulmonary Hypertension Market Report
Study Period: 2019–2032
Coverage: 7MM [The United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, Japan]
Key Chronic Pulmonary Hypertension Companies: Bayer, Attgeno AB, Cereno Scientific AB, Bial – Portela C S.A, Liquidia Technologies, Bellerophon Therapeutics, AbbVie, Tenax Therapeutics, Insmed, Altavant Sciences, and others
Key Chronic Pulmonary Hypertension Pipeline Therapies: Supernitro (PDNO), CS1, Zamicastat (BIA 5-1058), YUTREPIA (LIQ861 Inhaled Treprostinil), INOpulse® A, Levosimendan, Treprostinil palmitil, Rodatristat Ethyl, and others
Therapeutic Assessment: Chronic Pulmonary Hypertension current marketed and emerging therapies
Chronic Pulmonary Hypertension Market Dynamics: Chronic Pulmonary Hypertension market drivers and barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Unmet Needs, KOL’s views, Analyst’s views, Chronic Pulmonary Hypertension Market Access and Reimbursement

Table of Contents
1. Chronic Pulmonary Hypertension Market Key Insights
2. Chronic Pulmonary Hypertension Market Report Introduction
3. Chronic Pulmonary Hypertension Market Overview at a Glance
4. Chronic Pulmonary Hypertension Market Executive Summary
5. Disease Background and Overview
6. Chronic Pulmonary Hypertension Treatment and Management
7. Chronic Pulmonary Hypertension Epidemiology and Patient Population
8. Patient Journey
9. Chronic Pulmonary Hypertension Emerging Drugs
10. 7MM Chronic Pulmonary Hypertension Market Analysis
11. Chronic Pulmonary Hypertension Market Outlook
12. Potential of Current and Emerging Therapies
13. KOL Views
14. Chronic Pulmonary Hypertension Market Drivers
15. Chronic Pulmonary Hypertension Market Barriers
16. Unmet Needs
17. SWOT Analysis
18. Appendix
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us
Sandeep Joshi
info@delveinsight.com
+1(919)321-6187